Virologic Suppression Is Maintained After Change To Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (EFV/FTC/TDF) vs. Continuation of Current Antiretroviral Therapy: Study 073 -Results of 24-week Interim Efficacy Analyses by Edwin DeJesus given during the 11th European AIDS Conference / EACS powered by - MULTIWEBCAST

11th European AIDS Conference / EACS

LIST OF PRESENTATIONS

OTHER WEBCASTS

Webcasted Presentation

BROWSE:

Edwin DeJesus

Orlando

United States of America

Virologic Suppression Is Maintained After Change To Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (EFV/FTC/TDF) vs. Continuation of Current Antiretroviral Therapy: Study 073 -Results of 24-week Interim Efficacy Analyses

English

2007-10-26

PRESENTATION

16 slide(s)

Extra Features Available

SLIDE LIBRARY

Disclosure

Ad board, consultant and honorariums for GSK, GS, Roche, Tibotec and BMS

Disclaimer ^{AMENDED ON January 29, 2009} | Close This Window | Technical Support

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.

Search’n Build™ Search presentations by keyword and instantly build your own highlight of the conference!

Search’n Build™
Search presentations by keyword and instantly build your own highlight of the conference!